Safety of beta‐nicotinamide mononucleotide (β‐NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC
Randomized trial evaluates safety and bioavailability of beta-nicotinamide mononucleotide in adults, suggesting its safety for use in food supplements.
Key Points
To assess the safety and bioavailability of β-NMN as a novel food source of niacin.
Evaluation based on Regulation (EU) 2015/2283
Human intervention study comparing bioavailability of β-NMN and nicotinamide
90-day oral toxicity study in rats
No safety concerns regarding β-NMN identified for adult use under proposed conditions
Bioavailability of nicotinamide from β-NMN determined to be equivalent with a conversion factor of 1
NOAEL identified at 400 mg/kg bw per day with MoE of 93